 | • レポートコード：MRC23Q36221 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、85ページ • 納品方法：Eメール（2-3日） • 産業分類：新技術 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の核酸医薬品市場について調査・分析し、世界の核酸医薬品市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他）、用途別セグメント分析（遺伝病、がん、循環器疾患、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Sarepta Therapeutics、Ionis Pharmaceuticals、Alnylam、Mina Therapeutics、BioNTech、NeXstar Pharmaceuticals、Nippon Shinyaku、Moderna Therapeutics、CureVac、Regulus Therapeutics、Miragen Therapeuticsなどが含まれています。世界の核酸医薬品市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、核酸医薬品市場規模を推定する際に考慮しました。本レポートは、核酸医薬品の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、核酸医薬品に関するビジネス上の意思決定に役立てることを目的としています。 ・核酸医薬品市場の概要 - 核酸医薬品のタイプ別セグメント - 世界の核酸医薬品市場規模：タイプ別分析（アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他） - 核酸医薬品の用途別セグメント - 世界の核酸医薬品市場規模：用途別分析（遺伝病、がん、循環器疾患、その他） - 世界の核酸医薬品市場規模予測（2018年-2029年） ・核酸医薬品市場の成長トレンド - 核酸医薬品の地域別市場規模（2018年-2029年） - 核酸医薬品市場ダイナミクス - 核酸医薬品の業界動向 - 核酸医薬品市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：アンチセンス核酸医薬品、siRNA医薬品、saRNA医薬品、miRNA医薬品、mRNA医薬品、その他 - 世界の核酸医薬品のタイプ別市場規模（2018年-2023年） - 世界の核酸医薬品のタイプ別市場規模（2024年-2029年） ・用途別セグメント：遺伝病、がん、循環器疾患、その他 - 世界の核酸医薬品の用途別市場規模（2018年-2023年） - 世界の核酸医薬品の用途別市場規模（2024年-2029年） ・核酸医薬品の地域別市場規模 - 北米の核酸医薬品市場規模（2018年-2029年） - アメリカの核酸医薬品市場規模（2018年-2029年） - ヨーロッパの核酸医薬品市場規模（2018年-2029年） - アジア太平洋の核酸医薬品市場規模（2018年-2029年） - 中国の核酸医薬品市場規模（2018年-2029年） - 日本の核酸医薬品市場規模（2018年-2029年） - 韓国の核酸医薬品市場規模（2018年-2029年） - インドの核酸医薬品市場規模（2018年-2029年） - オーストラリアの核酸医薬品市場規模（2018年-2029年） - 中南米の核酸医薬品市場規模（2018年-2029年） - 中東・アフリカの核酸医薬品市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Sarepta Therapeutics、Ionis Pharmaceuticals、Alnylam、Mina Therapeutics、BioNTech、NeXstar Pharmaceuticals、Nippon Shinyaku、Moderna Therapeutics、CureVac、Regulus Therapeutics、Miragen Therapeutics ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Nucleic Acid Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Nucleic Acid Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Nucleic Acid Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Nucleic Acid Drugs in Genetic Disease is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Nucleic Acid Drugs include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Mina Therapeutics, BioNTech, NeXstar Pharmaceuticals, Nippon Shinyaku, Moderna Therapeutics and CureVac, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid Drugs.
The Nucleic Acid Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nucleic Acid Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Mina Therapeutics
BioNTech
NeXstar Pharmaceuticals
Nippon Shinyaku
Moderna Therapeutics
CureVac
Regulus Therapeutics
Miragen Therapeutics
Segment by Type
Antisense Nucleic Acid Drugs
siRNA Drugs
saRNA Drugs
miRNA Drugs
mRNA Drugs
other
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Antisense Nucleic Acid Drugs
1.2.3 siRNA Drugs
1.2.4 saRNA Drugs
1.2.5 miRNA Drugs
1.2.6 mRNA Drugs
1.2.7 other
1.3 Market by Application
1.3.1 Global Nucleic Acid Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid Drugs Market Perspective (2018-2029)
2.2 Nucleic Acid Drugs Growth Trends by Region
2.2.1 Global Nucleic Acid Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nucleic Acid Drugs Historic Market Size by Region (2018-2023)
2.2.3 Nucleic Acid Drugs Forecasted Market Size by Region (2024-2029)
2.3 Nucleic Acid Drugs Market Dynamics
2.3.1 Nucleic Acid Drugs Industry Trends
2.3.2 Nucleic Acid Drugs Market Drivers
2.3.3 Nucleic Acid Drugs Market Challenges
2.3.4 Nucleic Acid Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid Drugs Players by Revenue
3.1.1 Global Top Nucleic Acid Drugs Players by Revenue (2018-2023)
3.1.2 Global Nucleic Acid Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Nucleic Acid Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nucleic Acid Drugs Revenue
3.4 Global Nucleic Acid Drugs Market Concentration Ratio
3.4.1 Global Nucleic Acid Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Drugs Revenue in 2022
3.5 Nucleic Acid Drugs Key Players Head office and Area Served
3.6 Key Players Nucleic Acid Drugs Product Solution and Service
3.7 Date of Enter into Nucleic Acid Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid Drugs Breakdown Data by Type
4.1 Global Nucleic Acid Drugs Historic Market Size by Type (2018-2023)
4.2 Global Nucleic Acid Drugs Forecasted Market Size by Type (2024-2029)
5 Nucleic Acid Drugs Breakdown Data by Application
5.1 Global Nucleic Acid Drugs Historic Market Size by Application (2018-2023)
5.2 Global Nucleic Acid Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nucleic Acid Drugs Market Size (2018-2029)
6.2 North America Nucleic Acid Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nucleic Acid Drugs Market Size by Country (2018-2023)
6.4 North America Nucleic Acid Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid Drugs Market Size (2018-2029)
7.2 Europe Nucleic Acid Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nucleic Acid Drugs Market Size by Country (2018-2023)
7.4 Europe Nucleic Acid Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid Drugs Market Size (2018-2029)
8.2 Asia-Pacific Nucleic Acid Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nucleic Acid Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Nucleic Acid Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid Drugs Market Size (2018-2029)
9.2 Latin America Nucleic Acid Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nucleic Acid Drugs Market Size by Country (2018-2023)
9.4 Latin America Nucleic Acid Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid Drugs Market Size (2018-2029)
10.2 Middle East & Africa Nucleic Acid Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nucleic Acid Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Nucleic Acid Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Detail
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Introduction
11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Detail
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2018-2023)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Detail
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Nucleic Acid Drugs Introduction
11.3.4 Alnylam Revenue in Nucleic Acid Drugs Business (2018-2023)
11.3.5 Alnylam Recent Development
11.4 Mina Therapeutics
11.4.1 Mina Therapeutics Company Detail
11.4.2 Mina Therapeutics Business Overview
11.4.3 Mina Therapeutics Nucleic Acid Drugs Introduction
11.4.4 Mina Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023)
11.4.5 Mina Therapeutics Recent Development
11.5 BioNTech
11.5.1 BioNTech Company Detail
11.5.2 BioNTech Business Overview
11.5.3 BioNTech Nucleic Acid Drugs Introduction
11.5.4 BioNTech Revenue in Nucleic Acid Drugs Business (2018-2023)
11.5.5 BioNTech Recent Development
11.6 NeXstar Pharmaceuticals
11.6.1 NeXstar Pharmaceuticals Company Detail
11.6.2 NeXstar Pharmaceuticals Business Overview
11.6.3 NeXstar Pharmaceuticals Nucleic Acid Drugs Introduction
11.6.4 NeXstar Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2018-2023)
11.6.5 NeXstar Pharmaceuticals Recent Development
11.7 Nippon Shinyaku
11.7.1 Nippon Shinyaku Company Detail
11.7.2 Nippon Shinyaku Business Overview
11.7.3 Nippon Shinyaku Nucleic Acid Drugs Introduction
11.7.4 Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2018-2023)
11.7.5 Nippon Shinyaku Recent Development
11.8 Moderna Therapeutics
11.8.1 Moderna Therapeutics Company Detail
11.8.2 Moderna Therapeutics Business Overview
11.8.3 Moderna Therapeutics Nucleic Acid Drugs Introduction
11.8.4 Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023)
11.8.5 Moderna Therapeutics Recent Development
11.9 CureVac
11.9.1 CureVac Company Detail
11.9.2 CureVac Business Overview
11.9.3 CureVac Nucleic Acid Drugs Introduction
11.9.4 CureVac Revenue in Nucleic Acid Drugs Business (2018-2023)
11.9.5 CureVac Recent Development
11.10 Regulus Therapeutics
11.10.1 Regulus Therapeutics Company Detail
11.10.2 Regulus Therapeutics Business Overview
11.10.3 Regulus Therapeutics Nucleic Acid Drugs Introduction
11.10.4 Regulus Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023)
11.10.5 Regulus Therapeutics Recent Development
11.11 Miragen Therapeutics
11.11.1 Miragen Therapeutics Company Detail
11.11.2 Miragen Therapeutics Business Overview
11.11.3 Miragen Therapeutics Nucleic Acid Drugs Introduction
11.11.4 Miragen Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023)
11.11.5 Miragen Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details